FDA Refers Reckitt To FTC For Hindering Generic Suboxone

Law360, New York (February 25, 2013, 3:12 PM EST) -- The U.S. Food and Drug Administration on Friday approved the production of two generic versions of Reckitt Benckiser Pharmaceuticals Inc.’s opioid dependence treatment Suboxone, rebuking the company for hindering generic competition and requesting a Federal Trade Commission probe into its practices.

The FDA, in a letter responding to a citizen petition from Reckitt, accused the drugmaker of acting disingenuously in September when it said it would eventually discontinue sales of Suboxone tablets and instead sell only a dissolving film version it claims is less prone to accidental use by children. The agency approved generics from Actavis Inc. and Amneal Pharmaceuticals LLC....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS